Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study

BACKGROUND: Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and prevalent patients receiving macitentan for the first time. METHODS: Retrospective, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Escribano-Subias, Pilar, López, Raquel, Almenar, Luis, Lázaro, María, Forn, Ian, Torrent, Anna, Blanco, Isabel, Barberà, Joan Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265251/
https://www.ncbi.nlm.nih.gov/pubmed/32487059
http://dx.doi.org/10.1186/s12890-020-01197-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265251/
https://www.ncbi.nlm.nih.gov/pubmed/32487059
http://dx.doi.org/10.1186/s12890-020-01197-5

Ejemplares similares